a reply to:
angelchemuel
I've been looking into Pfizer-BioNtech-Fosun Pharmaceuticals more deeply.
I just came across something stunning.
Circling back to Albert Bourla's book "Moonshot"...
Page 23 "Michael knew from previous discussions that the speed of development and
THE ABILITY TO BOOST FREQUENTLY WERE VERY HIGH PRIORITIES FOR
ME."
He knew that by late 2020 there would be a variant and a more lethal one. Bourla also knew that Covid would mutate sooner than later.
As a result "it was important to have a vaccine that we could boost as often as was needed."
The only way to introduce these boosters was by using mRNA technology. "A traditional type of vaccine would take months to design, this mRNA would
need just a couple of weeks." Page 25
On page 28/29 Bourla discusses BioNTech commercialization rights and then vaguely refers to a Chinese company but never specifically names it!
"China was excluded from this agreement, as BioNTech already had an agreement with a Chinese company for China, Hong Kong, Macau and
Taiwan."
That would be Fosun Pharmaceuticals.
No better words ever spoken *"
"Our problem is not that we aim too high and miss, but we aim too low and hit."
Aristotle, 384-322 BC
--------------------
Page 52. How did Pfizer decide on which candidate to use? There were two. BNT 162b1 and BNT 162b2. 80% of their data was from BNT 162b1 and "and we
couldn't afford time to develop additional data for b2."
July 24,2020 [17] Bourla made the critical decision to go with b2 with fingers crossed. This makes zero sense.
Here's where things get interesting wrt Fosun Pharmaceuticals. August 5, 2020 [17] Fosun, which had received marketing rights from BioNTech, conducted
clinical trials. They tested BNT 162b1, the candidate that they had 80% data, and remember China has never approved the use of any of the mRNA jabs.
Pfizer went with b2 world wide with very little data.
Fosun Pharmaceuticals Wiki
Interesting factoid BioNTech owns 50% of the pharmaceutical facility in China.
Fosun and BioNTech
I should probably re read this book with a fresh pair of eyes.